Keros Therapeutics, Inc.
KROS | US
Overview
Corporate Details
- ISIN(s):
- US4923271013
- LEI:
- Country:
- United States of America
- Address:
- 1050 WALTHAM STREET, SUITE 302, 2421 LEXINGTON
- Website:
- https://www.kerostx.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Keros Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Keros Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Keros Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France
COX
France
COX
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
United States of America
NLSP
Develops a non-invasive electric field therapy to disrupt and treat aggressive solid tumor cancers.
United States of America
NVCR
United States of America
NVCR
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
United Kingdom
NFX
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
United States of America
NRIX
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
South Korea
244460
United States of America
OABIW
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom
ONC
United Kingdom
ONC
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
South Korea
382150
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
France
ALONC